We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00774488
Recruitment Status : Completed
First Posted : October 17, 2008
Last Update Posted : October 17, 2008
German Research Foundation
Information provided by:
German Institute of Human Nutrition

Brief Summary:
This clinical, randomized, cross-over study in obese healthy subjects aimed to analyse the acute effects of the incretin hormon Glucose Dependent Insulinotropic Polypeptide (GIP) on metabolic parameters and gene expression in subcutaneous adipose tissue.

Condition or disease Intervention/treatment
Metabolic Syndrome Obesity Insulin Sensitivity Other: Glucose dependent insulinotropic polypeptide (GIP)

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Study Start Date : January 2006
Primary Completion Date : July 2007
Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Intervention Details:
    Other: Glucose dependent insulinotropic polypeptide (GIP)
    GIP-Infusions for 4 h in a postprandial concentration

Primary Outcome Measures :
  1. Changes in gene expression of subcutaneous adipose tissue with microarray analysis [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Analysis of inflammatory marker (blood levels and gene expression), Activity of 11beta HSD and 11-beta HSD mRNA in adipose tissue, etc. [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI > 28
  • Healthy subjects
  • Normal glucose tolerance

Exclusion Criteria:

  • Diabetes,IFG, IGT
  • Chronical-inflammatory diseases
  • Hb < 12g/dl
  • Elevation in liver enzymes or creatinin concentrations
  • Great weight changes within last 12 months
  • Any cancer diagnosis in last 10 years

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AFH. Pfeiffer, German Institute of Human Nutrition
ClinicalTrials.gov Identifier: NCT00774488     History of Changes
Other Study ID Numbers: GIP-Genexpression Study
First Posted: October 17, 2008    Key Record Dates
Last Update Posted: October 17, 2008
Last Verified: October 2008

Keywords provided by German Institute of Human Nutrition:
Euglycemic-hyperinsulinemic clamp
fat biopsies
microarray analysis
quantitative real time PCR
low grade-inflammation

Additional relevant MeSH terms:
Metabolic Syndrome X
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Gastric Inhibitory Polypeptide
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs